Dapagliflozin clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Dapagliflozin Clinical Uses: Type 2 Diabetes Management
Dapagliflozin is primarily used to treat type 2 diabetes. It works by inhibiting the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, which increases glucose excretion in urine and lowers blood sugar levels. Its action is independent of insulin, making it suitable as both monotherapy (especially for those intolerant to metformin) and as an add-on to other glucose-lowering drugs, including insulin, when diet and exercise alone are not enough to control blood sugar Plosker2014Dhillon2019Meng2008. Clinical studies show that dapagliflozin consistently reduces HbA1c, fasting plasma glucose, and body weight, with effects maintained over several years Plosker2014Dhillon2019. It is generally well tolerated, with a low risk of hypoglycemia unless combined with other hypoglycemic agents Plosker2014Dhillon2019.
Dapagliflozin for Cardiovascular and Heart Failure Benefits
Dapagliflozin has demonstrated significant benefits for patients with cardiovascular disease and heart failure. It reduces the risk of cardiovascular death and hospitalization for heart failure, and may also lower the progression of renal disease in patients with established atherosclerotic cardiovascular disease or multiple risk factors . In acute heart failure, dapagliflozin provides symptomatic relief, improves diuresis, and reduces rehospitalization rates, although its effect on mortality is not significant in the short term . Animal studies also show that dapagliflozin can protect the heart during ischemia/reperfusion injury by reducing infarct size, improving heart function, and decreasing arrhythmias .
Dapagliflozin in Chronic Kidney Disease (CKD)
Dapagliflozin is widely used for treating chronic kidney disease, including in elderly patients. It helps stabilize kidney function, reduces proteinuria, and is associated with improved liver function without negatively affecting muscle mass or strength . In non-diabetic models of cardiorenal syndrome, dapagliflozin protects the kidneys by reducing inflammation, fibrosis, oxidative stress, and modulating the renin-angiotensin-aldosterone system . These findings support its use as part of a comprehensive approach to CKD management .
Dapagliflozin for Nonalcoholic Fatty Liver Disease (NAFLD)
Recent studies and meta-analyses indicate that dapagliflozin can be effective in treating nonalcoholic fatty liver disease. It reduces liver enzymes, triglycerides, body weight, and improves metabolic indicators, suggesting potential therapeutic benefits for NAFLD Li2021He2022. The drug appears to work by promoting autophagy and fatty acid oxidation in the liver, which helps reduce fat accumulation .
Pediatric and Special Populations
Dapagliflozin has been studied in children and adolescents, mainly for type 2 diabetes, chronic kidney disease, and heart failure. In pediatric type 2 diabetes, it effectively lowers HbA1c and is generally well tolerated, with mild side effects such as hypoglycemia when used with other hypoglycemic drugs . Early evidence also suggests safety and potential benefits in children with kidney disease and heart failure .
Safety and Tolerability
Dapagliflozin is generally well tolerated. The most common side effects are genital infections, especially in women, and a low risk of hypoglycemia, mainly when used with other glucose-lowering drugs Plosker2014Dhillon2019. Diabetic ketoacidosis is rare but can occur, particularly in children . Dapagliflozin is not recommended for patients with moderate or severe renal impairment .
Conclusion
Dapagliflozin is a versatile medication with established uses in type 2 diabetes, heart failure, and chronic kidney disease. It also shows promise for nonalcoholic fatty liver disease and is being explored in pediatric populations. Its benefits include improved glycemic control, cardiovascular and renal protection, and favorable effects on body weight and metabolic health, with a generally good safety profile Plosker2014Dhillon2019Li2021+5 MORE.
Sources and full results
Most relevant research papers on this topic